Evidence map›Paper›PMID 38116825›Full record

ArticleGigaScience2022

DrugSim2DR: systematic prediction of drug functional similarities in the context of specific disease for drug repurposing.

Jiashuo Wu, Ji Li, Yalan He, Junling Huang, Xilong Zhao, Bingyue Pan, Yahui Wang, Liang Cheng, Junwei Han

Open access · goldAbstract read
In one paragraph

Article in GigaScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. DrugRepoBank: a comprehensive database and discovery platform for accelerating drug repositioning.Database : the journal of biological databases and curation · 2024
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jiashuo WuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.ORCID 0009-0002-8126-1984
Ji LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Yalan HeCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Junling HuangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Xilong ZhaoCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Bingyue PanCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Yahui WangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Liang ChengCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.ORCID 0000-0002-6665-6710
Junwei HanCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.ORCID 0000-0002-3276-0819
Harbin Medical University · CN

Funding

National Natural Science Foundation of China 62072145Natural Science Foundation of Heilongjiang Province LH2019C042
6 · The paper itself

Abstract

backgroundTraditional approaches to drug development are costly and involve high risks. The drug repurposing approach can be a valuable alternative to traditional approaches and has therefore received considerable attention in recent years.

findingsHerein, we develop a previously undescribed computational approach, called DrugSim2DR, which uses a network diffusion algorithm to identify candidate anticancer drugs based on a drug functional similarity network. The innovation of the approach lies in the drug-drug functional similarity network constructed in a manner that implicitly links drugs through their common biological functions in the context of a specific disease state, as the similarity relationships based on general states (e.g., network proximity or Jaccard index of drug targets) ignore disease-specific molecular characteristics. The drug functional similarity network may provide a reference for prediction of drug combinations. We describe and validate the DrugSim2DR approach through analysis of data on breast cancer and lung cancer. DrugSim2DR identified some US Food and Drug Administration-approved anticancer drugs, as well as some candidate drugs validated by previous studies in the literature. Moreover, DrugSim2DR showed excellent predictive performance, as evidenced by receiver operating characteristic analysis and multiapproach comparisons in various cancer datasets.

conclusionsDrugSim2DR could accurately assess drug-drug functional similarity within a specific disease context and may more effectively prioritize disease candidate drugs. To increase the usability of our approach, we have developed an R-based software package, DrugSim2DR, which is freely available on CRAN (https://CRAN.R-project.org/package=DrugSim2DR).

Indexed as

Antineoplastic AgentsBreast NeoplasmsAlgorithmsDrug RepositioningFemaleHumansPharmaceutical PreparationsAntineoplastic AgentsPharmaceutical Preparationscomputational drug repurposingdrug–drug similaritynetwork analysisspecific disease state

Identifiers

PMID38116825
PMCPMC10729734
OpenAlexW4389932327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.